iStock-1130915055_ajustes.jpg

Transform the patients' world

Discover Our Noble Purpose
Header

Our Purpose

This is Almirall's legacy for future generations, it is our contribution to society.

R&D - therapeutical areas: Derma

We are driven by science, diligent by nature. Our medicines help to make a significant difference to patients’ lives by treating a wide of range of skin diseases.

INTERNATIONAL PRESENCE

A global company close at hand

Almirall has consolidated international coverage on a global scale thanks to owned subsidiaries and sales agreements with the most prestigious partners in key markets such as the USA, Japan and China.

15Affiliates in EU & US

20Countries with direct presence

+100Countries with partnership agreements

Our global presence

We are where you need us to be

Our extensive product portfolio is available in more than 100 countries – either through the 15 affiliates or via the network of strategic partnerships that we have developed over time. Our focus is global and since our beginnings we have grown our coverage to be where you need us to be.

Spain

Almirall, S.A.
General Mitre, 151
08022 Barcelona - España
+34 93 291 30 00

Contact

United States

Almirall, LLC – U.S.
101 Lindenwood,
Dr., Suite 400
19355 Malvern, PA
USA

Poland

Almirall Sp. z o.o.
Ul Pileckiego 63
02-781 Warszawa
Polska
+48- 22 330 0257

Contact

Portugal

Almirall - Produtos Farmacêuticos, Lda.
Rua do Central Park
Edificio 3, numero 6, 4B
2795-242 Linda A Velha
Portugal
+351 214 155750

Italy

Almirall, S.p.A.
Via Messina, 38 Torre C
20154 - Milano
Italia
+39 02 34 618 1

Contact

Switzerland

Almirall AG
Alte Winterthurerstrasse 14
CH-8304 Wallisellen
Schweiz
+41 (0) 44 834 9000

Contact

France

Almirall SAS
Immeuble Dueo
5 boulevard Gallieni
92130 Issy-les-Moulineaux
+33 01 46 46 19 20

Contact

United Kingdom

Almirall Ltd
Harman House
1 George St
Uxbridge
Middlesex UB8 1QQ
United Kingdom
+44 (0)20 7160 2500

Contact

Belgium

Almirall NV
Arianelaan 5
1200 Brussels
Belgique
+32 2 771 86 37

Netherlands

Almirall B.V.
Papendorpseweg 100
3528 BJ Utrecht, Netherlands
+31 - 30 799 1155

Contact

Germany

Almirall Hermal GmbH
Scholtzstraße 3
21465 Reinbek
Deutschland
+49 (0) 40 727 04-0

Contact

Nordic Countries

Vandtårnsvej 77
2860 Søborg
Denmark
+45 70257575

Austria

Almirall GmbH
Breitenfurter Str. 113, Top 101
A-1120 Vienna
Österreich
+43 (0) 1 595 39 60

Contact

Czechia

Pujmanové 1753/10a. Praha 4
140 00, Czech Republic

Contact

Slovakia

Prievozská 4D, Bratislava, 821 09

Contact

Almirall’s Leadership and Governance

As a publicly listed company and for the benefit of both the financial markets and the general public, Almirall pursues an open and active information policy.

Our history

Almirall has been caring for people since 1944

1944

Our company was founded in Barcelona

1984

We develop and launched a leading antacid treatment

1990

We progress in the field of antihistamics in Spain and we started licencing our products internationally.

2000

We obtain the U.S. Food and Drug Administration (FDA) approval for an own R&D antimigraine treatment.

2007

We acquired Hermal, a European skincare business previously owned by Reckitt Benckiser.

2013

Aqua Pharmaceuticals, a North American skincare company, was acquired.

2015

We continued our acquisition strategy in skincare by buying Poli Group, world leader in nail and skin diseases.

2017

In June of that year, the European Commission approved a new Fumaric Acid Ester of our own R&D to treat psoriasis. In December, same year, we announced a collaboration agreement to develop a treatment for actinic keratosis and other skin conditions, both in Europe and the USA.

2019

In January of that year, our US subsidiary announced the launch of the first antibiotic treatment specifically developed for acne. We also obtained the rights for developing a humanized monoclonal antibody in Europe for the treatment of atopic dermatitis.

1960

We began activities in research and development

1987

We became the Pharmaceutical Industry Spanish market leader

1997

We created Almirall Prodesfarma Laboratories as a result of the merger between Almirall and Prodesfarma Pharmaceutical Groups.

2005

We gained the commercial rights for distributing a cannabinoid based medicine in Europe, for patients with Multiple Sclerosis.

2012

The EMA and the FDA approves the commercialization of Almirall's bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in Europe and the USA.

2014

We transferred the rights for our respiratory franchise to the AstraZeneca company.

2016

Sun Pharmaceutical Industries signed an agreement with us to develop and commercialise a new biological treatment for psoriasis in Europe.

2018

We reached an agreement with Allergan to acquire five products from their US skincare business to treat acne and dermatosis.

Our responsibility

Almirall is committed to working with you on a basis of respect and integrity. We understand there are many people affected by what we do, including patients, healthcare professionals, our partners, peers and other stakeholders.

Learn more about our commitments

You might be interested in...

Caring of your skin

We put ourselves in your shoes to understand your conditions.

R&D Pipeline

Focus on medical needs. Provide treatment solutions for both today’s and future generations.

Patient associations

Almirall discloses its support to patient organizations in accordance with the EFPIA Code of Practice.